New Panel Launched: ACTBRCA HRD

2019-03-07

ACTBRCA® HRD is a new panel designed to evaluate whether a patient is likely to benefit from PARP inhibitors. ACTBRCA® HRD sequences 48 genes to detect mutations in BRCA1/2 and other homologous recombination repair (HRR) genes. In addition to germline BRCA mutations covered by other BRCA tests, ACTBRCA® HRD provides more comprehensive information by also detecting BRCA germline large genomic rearrangement (LGR), BRCA somatic mutations in tumor samples, and other HRR-related mutations, allowing physicians to identify more patients suitable for PARP inhibitors. 


More Info on ACTBRCA® HRD